Qualitative Concept – Page 52

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

11 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Siemens Healthineers Secures FDA Approval for Revolutionary 3D Mammography System with 5-Second Acquisition Time

11 months ago talkbio0Tagged 3 Days, Approved, Malignant neoplasm of breast, Mammography, Mammomat B.brilliant, Optical Image Reconstruction, PlatinumTomo, Screening for cancer, Siemens Healthineers, tomosynthesis, UltraHD, United States Food and Drug Administration, wide-angle technology

Siemens Healthineers, FDA approval, 3D mammography, Mammomat B.brilliant, breast cancer screening, wide-angle technology, tomosynthesis, PlatinumTomo, UltraHD image reconstruction.

Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing

11 months ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, pharmaceutical manufacturing, Wegovy, Weight-Loss Agents, Zepbound

Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

12 months ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

12 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses